Related Experiment Video
Updated: Oct 8, 2025
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Management of Psoriasis During the Coronavirus Disease 2019 Pandemic
Kathryn Jayne Tan1,2, Maria Rosa Noliza Encarnacion1,2, Olga Marushchak1,2
1Drs. Tan, Encarnacion, and Anvekar and Ms. Marushchak are with the Department of Dermatology, Icahn School of Medicine at Mount Sinai in New York, New York.
Insights
The COVID-19 pandemic impacts psoriasis management due to immune system similarities. Personalized treatment decisions are crucial, balancing benefits and risks for each patient.
Area of Science:
- Immunology
- Dermatology
- Infectious Diseases
Background:
- Coronavirus disease 2019 (COVID-19) emerged in late 2019, prompting global research into its effects, particularly in individuals with pre-existing conditions.
- Immune system dysregulation observed in COVID-19 patients shares similarities with the pathophysiology of psoriasis.
- The COVID-19 pandemic has significantly influenced the management of psoriasis, affecting both ongoing and new treatment strategies.
Purpose of the Study:
- To summarize current data on the relationship between psoriasis and COVID-19.
- To provide insights into safety considerations for managing psoriasis during the pandemic.
- To highlight the need for personalized treatment approaches.
Main Methods:
- A comprehensive review of available data from PubMed.
- Manual review of reference lists from included articles.
Main Results:
- Increasing literature explores the psoriasis-COVID-19 relationship from various viewpoints.
- Evidence guiding psoriasis management during the pandemic may be limited.
- Current literature offers potential clues for safety considerations in psoriasis care.
Conclusions:
- Personalized treatment strategies are essential for managing psoriasis during the COVID-19 pandemic.
- Each treatment approach requires a careful, individualized assessment of benefits and risks.
- The review aims to inform clinical decision-making despite potential evidence gaps.
Abstract:
Coronavirus disease 2019 (COVID-19) was first reported in late December 2019 and, since then, has rapidly taken over the globe, with the scientific world furiously working to gather more data on its effect on people with and without concurrent conditions. The dysregulation of the immune system noted in COVID-19 patients is said to be similar to that seen with psoriasis. The pandemic has affected the management of psoriasis, not only for those under treatment but also those about to begin a new therapy. There has been an increasing number of studies in the current literature focusing on the relationship between psoriasis and COVID-19, offering different perspectives. This is a summary of available data in PubMed supplemented by a manual review of reference lists of included articles. There may be lack of robust evidence to drive approaches to the management of psoriasis during the pandemic; however, we hope that the current literature may provide some clues for safety considerations. The conclusion of this article is that each approach to treatment should be personalized, weighing the benefits and risks in each case separately.
More Related Videos
Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:21Rheumatic Heart Disease III: Medical Management
01:30Asthma-IV: Nursing Management
First, in...
01:17Pericarditis III: Medical Management
01:26COPD: Management Using Bronchodilators and Corticosteroids